SHP2 inhibitor

SI-7053

SHP2 inhibitor, >98% (HPLC)

IUPAC Name : (2S,3S)-8-(5-((3-Chloro-2-((4-(7-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)amino)pyridin-4-yl)thio)pyrazin-2-yl)-2-methyl-1-oxa-8-azaspiro[4.5]decan-3-amine

Price And Availability
Pack Size	Price in USD	Add To Shopping Cart	Availability	Shipping Status
5MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
10MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
25MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
50MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026
100MG	Request A Quote		Back Order	Estimated to ship on 04 October 2026

Applications : This lead compound is a potent dual SHP2 (IC₅₀ = 4.3 nM) and CDK4 (IC₅₀ = 18.2 nM) inhibitor that induces G0/G1 arrest and suppresses proliferation in TNBC cell lines. It shows favorable oral pharmacokinetics (F = 45.8%) and significant antitumor efficacy in the EMT6 syngeneic mouse model. Western blot and immunohistochemistry confirm effective SHP2/CDK4 target engagement and immune activation in tumors. As the first SHP2–CDK4 dual inhibitor, it represents a promising candidate for further TNBC drug development.

References : Chen X. et al.: J. Med Chem., 65(9), 6729-6747, 2022.

Storage : Keep container tightly closed under nitrogen or argon and refrigerate for long-term shelf life.

Caution : In case of contact with skin or eyes, rinse immediately with plenty of water and seek medical advice. Wear suitable protective clothing and gloves.